DBP B — Double Bond Pharmaceutical International AB (publ) Income Statement
0.000.00%
- SEK46.93m
- SEK45.45m
- SEK1.37m
Annual income statement for Double Bond Pharmaceutical International AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.241 | 1.16 | 0.956 | 1.24 | 1.37 |
Cost of Revenue | |||||
Gross Profit | -7.83 | -12.4 | -15.2 | -10.4 | -7.56 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 8.35 | 17.7 | 10.2 | 16.4 | 14.8 |
Operating Profit | -8.11 | -16.5 | -9.26 | -15.2 | -13.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.13 | -17.7 | -9.26 | -15.2 | -17.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.13 | -17.7 | -9.26 | -15.2 | -17.3 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -7.82 | -17.7 | -9.26 | -15.2 | -17.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.82 | -17.7 | -9.26 | -15.2 | -17.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.228 | -0.336 | -0.14 | -0.201 | -0.19 |
Dividends per Share |